BR9914601A - Inibidor de topoisomerase capturado por lipossoma - Google Patents
Inibidor de topoisomerase capturado por lipossomaInfo
- Publication number
- BR9914601A BR9914601A BR9914601-0A BR9914601A BR9914601A BR 9914601 A BR9914601 A BR 9914601A BR 9914601 A BR9914601 A BR 9914601A BR 9914601 A BR9914601 A BR 9914601A
- Authority
- BR
- Brazil
- Prior art keywords
- topoisomerase inhibitor
- liposomes
- liposome
- captured
- topoisomerase
- Prior art date
Links
- 239000003534 dna topoisomerase inhibitor Substances 0.000 title abstract 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: "INIBIDOR DE TOPOISOMERASE CAPTURADO POR LIPOSSOMA". é descrita uma composição para administração de uma dose terapeuticamente efetiva de um inibidor de topoisomerase 1 ou inibidor de topoisomerase 1/11. A composição inclui lipossomas tendo uma superfície externa e uma superfície interna definindo compartimentos lipossómicos aquosos, e sendo compostos por um lipídio formador de vesículas e um lipídio formador de vesículas derivatizado com um polímero hidrofílico para formar um revestimento de cadeias poliméricas hidrofílicas em ambos os lados interno e externo dos lipossomas. Capturado nos lipossomas encontra-se o inibidor de topoisomerase em uma concentração de pelo menos cerca de 0,10 <109>mol do medicamento por <109>mol do lipídio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10467198P | 1998-09-16 | 1998-09-16 | |
PCT/US1999/024228 WO2000023052A1 (en) | 1998-09-16 | 1999-10-15 | Liposome-entrapped topoisomerase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9914601A true BR9914601A (pt) | 2001-10-23 |
Family
ID=22301756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9914601-0A BR9914601A (pt) | 1998-09-16 | 1999-10-15 | Inibidor de topoisomerase capturado por lipossoma |
Country Status (18)
Country | Link |
---|---|
US (4) | US6355268B1 (pt) |
EP (1) | EP1121102B1 (pt) |
JP (1) | JP2002527466A (pt) |
KR (1) | KR100679906B1 (pt) |
CN (1) | CN1205923C (pt) |
AT (1) | ATE238039T1 (pt) |
AU (1) | AU774715B2 (pt) |
BR (1) | BR9914601A (pt) |
CA (1) | CA2346879A1 (pt) |
DE (1) | DE69907243T2 (pt) |
DK (1) | DK1121102T3 (pt) |
ES (1) | ES2198970T3 (pt) |
IL (1) | IL142573A0 (pt) |
NO (1) | NO20011844L (pt) |
NZ (1) | NZ511112A (pt) |
PT (1) | PT1121102E (pt) |
WO (1) | WO2000023052A1 (pt) |
ZA (1) | ZA200103063B (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1121102T3 (da) * | 1998-09-16 | 2003-08-11 | Alza Corp | Liposomindesluttede topoisomeraseinhibitorer |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
AU780194B2 (en) * | 1999-06-24 | 2005-03-10 | Kyowa Hakko Kirin Co., Ltd. | Method of regulating leakage of drug encapsulated in liposomes |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
AU2001258106A1 (en) * | 2000-05-11 | 2001-11-20 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
MXPA02012817A (es) * | 2000-06-30 | 2004-07-30 | Inex Pharmaceuticals Inc | Drogas antineoplasicas liposomales y uso de las mismas. |
US7452550B2 (en) * | 2000-06-30 | 2008-11-18 | Hana Biosciences, Inc. | Liposomal antineoplastic drugs and uses thereof |
BR0115260A (pt) * | 2000-11-09 | 2005-08-16 | Neopharm Inc | Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
EP1480691A4 (en) | 2002-03-05 | 2007-11-28 | Univ State Cleveland | AGGLOMERATED PARTICLES FOR ADMINISTERING AEROSOL DRUGS |
EP1393719A1 (en) * | 2002-08-23 | 2004-03-03 | Munich Biotech AG | Camptothecin-carboxylate formulations |
WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
DE60330745D1 (de) * | 2002-12-31 | 2010-02-11 | Bharat Serums & Vaccines Ltd | Nicht-pegylierte lang-zirkulierende Liposome |
CA2527130A1 (en) * | 2003-04-02 | 2004-10-14 | Paul Tardi | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
EP1618897A4 (en) * | 2003-04-04 | 2010-09-29 | Eisai R&D Man Co Ltd | LIPID MEMBRANE STRUCTURE COMPRISING AN ANTI-MT-MMP MONOCLONAL ANTIBODY |
US20040204435A1 (en) * | 2003-04-09 | 2004-10-14 | Joachim Liehr | Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US20060222694A1 (en) * | 2003-06-27 | 2006-10-05 | Oh Choon K | Stabilized topotecan liposomal composition and methods |
CN100431525C (zh) * | 2003-07-17 | 2008-11-12 | 台湾东洋药品工业股份有限公司 | 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物 |
WO2005037911A2 (en) | 2003-08-26 | 2005-04-28 | Smithkline Beecham Corporation | Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
EP1677765A1 (en) * | 2003-10-24 | 2006-07-12 | Alza Corporation | Preparation of lipid particles |
CN100423778C (zh) * | 2003-11-25 | 2008-10-08 | 上海复旦张江生物医药股份有限公司 | 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用 |
JPWO2005053643A1 (ja) * | 2003-12-01 | 2007-06-28 | 三菱ウェルファーマ株式会社 | リポソーム |
US20050129750A1 (en) * | 2003-12-15 | 2005-06-16 | Yu-Fang Hu | Process for producing liposome suspension and product containing liposome suspension produced thereby |
US20050129752A1 (en) * | 2003-12-15 | 2005-06-16 | Tty Biopharm Limited Company | Use and manufacturing process for liposomal doxorubicin pharmaceutical composition |
EP1547580A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
EP1547582A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Method of producing lipid complexed camptothecin-carboxylate |
EP1731172B1 (en) * | 2004-03-26 | 2013-06-05 | Terumo Kabushiki Kaisha | Liposome preparation |
US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
US7713517B2 (en) | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
PL1746976T3 (pl) * | 2004-05-03 | 2017-09-29 | Merrimack Pharmaceuticals, Inc. | Liposomy przydatne w systemie podawania leków |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
AU2011202665C1 (en) * | 2004-05-03 | 2014-04-24 | Ipsen Biopharm Ltd. | Liposomes useful for drug delivery |
BRPI0511753A (pt) * | 2004-06-01 | 2008-01-02 | Terumo Corp | formulação de irinotecano e respectiva composição farmacêutica |
US20080193509A1 (en) * | 2004-06-18 | 2008-08-14 | Terumo Kabushiki Kaisha | Liposome Preparation Containing Slightly Water-Soluble Camptothecin |
US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
JP5685357B2 (ja) | 2004-07-09 | 2015-03-18 | ロバート セービン, | 哺乳類疾病の治療のための組成物および使用法 |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
US8318200B1 (en) * | 2004-10-05 | 2012-11-27 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8663599B1 (en) * | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8318198B1 (en) * | 2004-10-05 | 2012-11-27 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
WO2006050327A2 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
WO2006052767A2 (en) * | 2004-11-05 | 2006-05-18 | Inex Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
JP5110880B2 (ja) * | 2004-11-18 | 2012-12-26 | テルモ株式会社 | 医薬組成物、製剤および組み合わせ製剤 |
US20090104254A1 (en) * | 2004-12-22 | 2009-04-23 | Rutgers, The State University Of New Jersey | Controlled Release Hydrogels |
US20070254019A1 (en) * | 2006-03-15 | 2007-11-01 | William Zamboni | Method for treating brain cancer |
US20070259031A1 (en) * | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics |
US20080081051A1 (en) * | 2006-09-28 | 2008-04-03 | Robert Sabin | Method of manufacturing anti-tumor and anti-viral compositions |
US20100047334A1 (en) * | 2006-10-06 | 2010-02-25 | Sofou Stavroula | Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes |
JP2010505880A (ja) * | 2006-10-06 | 2010-02-25 | ポリテクニック、インスティチュート、オブ、ニューヨーク、ユニバーシティー | pH感受性リポソーム組成物 |
JP5080779B2 (ja) * | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
WO2008070009A2 (en) * | 2006-12-01 | 2008-06-12 | Alza Corporation | Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2008079240A1 (en) * | 2006-12-19 | 2008-07-03 | Alza Corporation | Use of liposome-entrapped agents for treating tumors |
CN101209243B (zh) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
CA2676986A1 (en) * | 2007-02-01 | 2008-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition comprising a campothecin derivative |
WO2009073236A1 (en) | 2007-12-05 | 2009-06-11 | Marval Biosciences, Inc. | Nano-scale contrast agents and methods of use |
DE102008036227A1 (de) * | 2008-08-02 | 2010-02-04 | Volkswagen Ag | Verstellkinematik für eine Armlehne |
CN101601642A (zh) * | 2009-06-30 | 2009-12-16 | 沈阳药科大学 | 一种囊泡类给药***及其应用 |
US11357728B2 (en) | 2009-10-26 | 2022-06-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
US8871253B2 (en) | 2009-10-26 | 2014-10-28 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
EP2508170B1 (en) | 2009-12-03 | 2015-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Liposome of irinotecan or its hydrochloride and preparation method thereof |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
CN103501766B (zh) * | 2011-03-01 | 2016-08-17 | to-BBB控股股份有限公司 | 不良水溶性物质的高主动脂质体装载 |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
CN103655477B (zh) * | 2012-09-03 | 2017-06-23 | 唐为钢 | 一种恩替卡韦高密度脂蛋白包封制剂及其制备方法和用途 |
IN2015DN04310A (pt) | 2012-11-20 | 2015-10-16 | Spectrum Pharmaceuticals | |
US10220095B2 (en) * | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
WO2015061206A2 (en) | 2013-10-21 | 2015-04-30 | North Carolina State University | Methods and constructs for compound delivery |
CN104367550A (zh) * | 2014-11-18 | 2015-02-25 | 南京华威医药科技开发有限公司 | 一种贝洛替康长循环纳米脂质体及其制备方法 |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
US10123973B2 (en) * | 2015-06-11 | 2018-11-13 | Mashhad University Of Medical Science | Liposome composition for cancer treatment |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
EP3791876A1 (en) | 2015-08-21 | 2021-03-17 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
EP3360577A4 (en) * | 2015-10-07 | 2019-06-12 | Ensuiko Sugar Refining Co., Ltd. | LIPOSOME COMPRISING A TAXANE COMPOUND |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
SG11201903615WA (en) | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
CA3058127C (en) | 2017-03-31 | 2022-07-05 | Fujifilm Corporation | Liposome composition and pharmaceutical composition |
JP7036919B2 (ja) | 2018-06-20 | 2022-03-15 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
WO2020071349A1 (ja) | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
JPWO2022250015A1 (pt) | 2021-05-24 | 2022-12-01 | ||
EP4349337A1 (en) | 2021-05-24 | 2024-04-10 | FUJIFILM Corporation | Anti-tumor agent |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1270198A (en) * | 1984-08-08 | 1990-06-12 | Marcel B. Bally | Encapsulation of antineoplastic agents in liposomes |
US5244903A (en) | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE4119981C1 (pt) | 1991-06-18 | 1993-01-21 | Fa. Carl Freudenberg, 6940 Weinheim, De | |
US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
WO1994026253A1 (en) | 1993-05-19 | 1994-11-24 | The Liposome Company, Inc. | Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer |
WO1995008986A1 (en) * | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
JP2001501173A (ja) | 1996-08-23 | 2001-01-30 | アルザ コーポレイション | シスプラチン化合物を含有するリポソーム |
TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0949906A4 (en) | 1996-10-22 | 2004-11-24 | Hermes Biosciences Inc | LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
KR100711315B1 (ko) * | 1997-09-16 | 2007-04-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 리포좀 캄프토테신 제제 |
DK1121102T3 (da) * | 1998-09-16 | 2003-08-11 | Alza Corp | Liposomindesluttede topoisomeraseinhibitorer |
-
1999
- 1999-10-15 DK DK99954971T patent/DK1121102T3/da active
- 1999-10-15 WO PCT/US1999/024228 patent/WO2000023052A1/en not_active Application Discontinuation
- 1999-10-15 KR KR1020017004803A patent/KR100679906B1/ko not_active IP Right Cessation
- 1999-10-15 JP JP2000576827A patent/JP2002527466A/ja not_active Abandoned
- 1999-10-15 PT PT99954971T patent/PT1121102E/pt unknown
- 1999-10-15 CN CNB998122076A patent/CN1205923C/zh not_active Expired - Fee Related
- 1999-10-15 ES ES99954971T patent/ES2198970T3/es not_active Expired - Lifetime
- 1999-10-15 IL IL14257399A patent/IL142573A0/xx unknown
- 1999-10-15 BR BR9914601-0A patent/BR9914601A/pt not_active Application Discontinuation
- 1999-10-15 EP EP99954971A patent/EP1121102B1/en not_active Revoked
- 1999-10-15 DE DE69907243T patent/DE69907243T2/de not_active Expired - Fee Related
- 1999-10-15 CA CA002346879A patent/CA2346879A1/en not_active Abandoned
- 1999-10-15 NZ NZ511112A patent/NZ511112A/en unknown
- 1999-10-15 US US09/419,189 patent/US6355268B1/en not_active Expired - Lifetime
- 1999-10-15 AU AU11189/00A patent/AU774715B2/en not_active Ceased
- 1999-10-15 AT AT99954971T patent/ATE238039T1/de not_active IP Right Cessation
-
2001
- 2001-04-10 NO NO20011844A patent/NO20011844L/no not_active Application Discontinuation
- 2001-04-12 ZA ZA200103063A patent/ZA200103063B/en unknown
- 2001-10-19 US US10/046,326 patent/US6465008B1/en not_active Expired - Lifetime
-
2002
- 2002-08-29 US US10/230,796 patent/US7244449B2/en not_active Expired - Lifetime
-
2004
- 2004-10-08 US US10/962,246 patent/US7279179B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050106231A1 (en) | 2005-05-19 |
KR20010075639A (ko) | 2001-08-09 |
ATE238039T1 (de) | 2003-05-15 |
AU1118900A (en) | 2000-05-08 |
JP2002527466A (ja) | 2002-08-27 |
IL142573A0 (en) | 2002-03-10 |
AU774715B2 (en) | 2004-07-08 |
WO2000023052A1 (en) | 2000-04-27 |
US6355268B1 (en) | 2002-03-12 |
CN1323199A (zh) | 2001-11-21 |
ZA200103063B (en) | 2001-10-18 |
CA2346879A1 (en) | 2000-04-27 |
NZ511112A (en) | 2003-11-28 |
US7279179B2 (en) | 2007-10-09 |
KR100679906B1 (ko) | 2007-02-07 |
ES2198970T3 (es) | 2004-02-01 |
US20020146450A1 (en) | 2002-10-10 |
NO20011844D0 (no) | 2001-04-10 |
US6465008B1 (en) | 2002-10-15 |
EP1121102B1 (en) | 2003-04-23 |
US20030133973A1 (en) | 2003-07-17 |
DE69907243T2 (de) | 2004-02-19 |
DK1121102T3 (da) | 2003-08-11 |
US7244449B2 (en) | 2007-07-17 |
DE69907243D1 (de) | 2003-05-28 |
PT1121102E (pt) | 2003-09-30 |
CN1205923C (zh) | 2005-06-15 |
EP1121102A1 (en) | 2001-08-08 |
NO20011844L (no) | 2001-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9914601A (pt) | Inibidor de topoisomerase capturado por lipossoma | |
ATE252372T1 (de) | Liposome enthaltend cisplatin | |
PT1083881E (pt) | Composicao de liposomas contendo um derivado de quinolona e uso da mesma como agente antibacteriano | |
PT932391E (pt) | Composicao lipossomal fusogenica e metodo | |
RU94045285A (ru) | Композиция против угрей с одновременным лечением поверхностных и глубоких слоев кожи и ее применение | |
FI980822A (fi) | Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi | |
CA2157410A1 (en) | Enhanced Circulation Effector Composition and Method | |
TR200101138T2 (tr) | Tedavi edici ajanlar ihtiva eden kaviteli implant | |
CA2308513A1 (en) | Method and composition for delivering zinc to the nasal membrane | |
DE69803940D1 (de) | Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe | |
ES2136883T3 (es) | Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol. | |
ES2188907T3 (es) | Dispositivo de soporte farmaceutico adecuado ppara la administracion de compuestos farmaceuticos a las superficies de las mucosas. | |
ATE378060T1 (de) | Verbessertes angereichertes blutplättchen wundheilmittel | |
BR0002688A (pt) | Camada de revestimento e uma camada de transferência de absorvente combinados | |
EP1140022B8 (en) | Method of administering a compound to multi-drug resistant cells | |
EE200000466A (et) | Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid | |
CA2327693A1 (en) | Use of phospholipids for the manufacture of a medicament for the prevention of adhesions | |
ES2174533T3 (es) | Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas. | |
EA199900750A1 (ru) | Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде | |
DE69635806D1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
ES2092559T3 (es) | Formulacion farmaceutica que contiene penciclovir. | |
DE59510583D1 (de) | Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid | |
DE59607949D1 (de) | Feste arzneimittelform mit polymerem material verteiltem wirkstoff | |
AU4975700A (en) | Absorbent article comprising topsheet with low surfactant or no synthetic surfactant | |
CO4750616A1 (es) | Hilo dental |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 13, 24 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |